{
    "clinical_study": {
        "@rank": "161464", 
        "acronym": "NTAH-Mod", 
        "arm_group": [
            {
                "arm_group_label": "Placebo for Probiotic", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo capsule that matches the probiotic capsule in appearance will be given once daily for 180 days."
            }, 
            {
                "arm_group_label": "Lactobacillus Rhamnosus GG", 
                "arm_group_type": "Active Comparator", 
                "description": "Dietary supplement capsule (Lactobacillus Rhamnosus GG) will be given once daily for 180 days."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being done to find out whether a diet supplemented with a probiotic nutrient\n      can improve alcoholic hepatitis and gut complications compared to routine standard care."
        }, 
        "brief_title": "Novel Therapies in Moderately Severe Acute Alcoholic Hepatitis", 
        "condition": "Acute Alcoholic Hepatitis", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis, Alcoholic", 
                "Hepatitis", 
                "Hepatitis A"
            ]
        }, 
        "detailed_description": {
            "textblock": "Aim 1: Evaluate the effects of probiotic supplements on improvement in MELD score and gut\n      mucosal integrity in patients with MELD < 21. Patients will be randomized to receive daily\n      probiotics for 6 months and standard of care treatment or placebo with standard care.\n\n      Aim 2: Document the natural history of moderately severe alcoholic hepatitis. Patients who\n      decline randomization will be offered the option of inclusion in the study prospectively for\n      data collection purposes and research study procedures.\n\n      Aim 3: Create a data and tissue biorepository. This biorepository will serve as a national\n      resource for studies related to acute alcoholic hepatitis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Ability to provide informed consent by subject or appropriate family member\n\n          2. Age between 21-70 years\n\n          3. Recent alcohol consumption > 50 g/d for > 6 months, continuing within two months\n             \u2028before enrollment\n\n          4. At least 2 of the following symptoms of acute alcoholic hepatitis: Anorexia, nausea,\n             \u2028right upper quadrant pain\n\n          5. Liver biopsy diagnostic of acute AH or at least 2 of the following: Jaundice,\n             leukocytosis, \u2028hepatomegaly\n\n          6. Elevation of AST > 80 U/L, but < 500 U/L; AST > ALT and ALT < 200 U/L; total\n             bilirubin \u2028> 3 mg/dL\n\n          7. Ultrasound or CT scan suggesting fatty infiltration of the liver OR liver biopsy\n             showing \u2028alcoholic hepatitis\n\n          8. Model for End-Stage Liver Disease (MELD) < 20\n\n        Exclusion Criteria:\n\n          1. Hypotension with blood pressure < 80/50 after volume repletion\n\n          2. Pregnancy; incarceration; inability to provide consent or lack of appropriate family\n             \u2028member\n\n          3. Signs of systemic infection: Fever > 39o C; positive blood or ascites cultures within\n             3 \u2028days of inclusion\n\n          4. Acute gastrointestinal bleeding requiring blood transfusion within the previous 4\n             days\n\n          5. Undue risk from immunosuppression: Positive HBsAg; a positive skin PPD skin test or\n             \u2028history of treatment for tuberculosis; history of any malignancy including\n             hepatocellular \u2028carcinoma; HIV infection\n\n          6. Previous treatment with corticosteroids or other immunosuppressive medications\n             \u2028including anti-TNF therapy, calcineurin inhibitors within the previous 3 months\n\n          7. ANA > 1:160; anti-smooth muscle antibody > 1:40; cryoglobulinemia; positive anti-CCP\n             \u2028or rheumatoid factor\n\n          8. Evidence of acute pancreatitis: CT evidence or amylase or lipase > 4 X upper limit of\n             normal\n\n          9. Serious cardiac, respiratory or neurologic disease or evidence of other liver\n             diseases \u2028such as autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing\n             cholangitis, Wilson disease, hemochromatosis, alpha-1-antitrypsin deficiency"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01922895", 
            "org_study_id": "UTSW_092012-012", 
            "secondary_id": "U01AA021893-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lactobacillus Rhamnosus GG", 
                "description": "Probiotic nutritional supplement; Lactobacillus Rhamnosus GG", 
                "intervention_name": "Lactobacillus Rhamnosus GG", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Culturelle"
            }, 
            {
                "arm_group_label": "Placebo for Probiotic", 
                "description": "Capsule manufactured without active ingredients.", 
                "intervention_name": "Placebo for Probiotic", 
                "intervention_type": "Drug", 
                "other_name": "Dummy capsule"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Alcoholic Hepatitis", 
            "MELD < 20", 
            "Probiotic", 
            "Nutritional Supplement", 
            "Lactobacillus Rhamnosus GG"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Craig J McClain, MD", 
                    "phone": "502-852-6991"
                }, 
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "University of Louisville"
                }, 
                "investigator": {
                    "last_name": "Craig J McClain, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Arthur J McCullough, MD", 
                    "phone": "216-444-2766"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic"
                }, 
                "investigator": {
                    "last_name": "Arthur J McCullough, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Mack.Mitchell@UTSouthwestern.edu", 
                    "last_name": "Mack C Mitchell, M.D.", 
                    "phone": "214-645-8300"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390"
                    }, 
                    "name": "U Texas Southwestern Medical Center"
                }, 
                "investigator": {
                    "last_name": "Mack C Mitchell, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Novel Therapies in Moderately Severe Acute Alcoholic Hepatitis", 
        "other_outcome": {
            "description": "Gut mucosal permeability will be measured by changes from baseline in the gut mucosal integrity as assessed by the lactulose/mannitol test.", 
            "measure": "Gut mucosal permeability", 
            "safety_issue": "No", 
            "time_frame": "180 days"
        }, 
        "overall_contact": {
            "email": "Mack.Mitchell@UTSouthwestern.edu", 
            "last_name": "Mack C Mitchell, M.D.", 
            "phone": "214-645-8300"
        }, 
        "overall_contact_backup": {
            "email": "Blair.Holbein@UTSouthwestern.edu", 
            "last_name": "Blair Holbein, PhD", 
            "phone": "214-648-5009"
        }, 
        "overall_official": {
            "affiliation": "U Texas Southwestern Medical Center", 
            "last_name": "Mack C Mitchell, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Data and Safety Monitoring Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "MELD scoring system for assessing the severity of chronic liver disease; MELD = 3.8[Ln serum bilirubin (mg/dL)] + 11.2[Ln INR] + 9.6[Ln serum creatinine (mg/dL)] + 6.4.", 
            "measure": "MELD score", 
            "safety_issue": "Yes", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01922895"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Texas Southwestern Medical Center", 
            "investigator_full_name": "Mack Mitchell", 
            "investigator_title": "Professor, Vice-Chair Internal Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Improvement in MELD score over 180 day study duration.", 
            "measure": "MELD score", 
            "safety_issue": "Yes", 
            "time_frame": "180 days"
        }, 
        "source": "University of Texas Southwestern Medical Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "The Cleveland Clinic", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Massachusetts, Worcester", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Louisville", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Texas Southwestern Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}